Biocon Limited’s shares surged by 2% after the company and its European partner Zentiva have achieved a major milestone with EU approval for their Liraglutide formulation.
The companies secured European Union approval for their Liraglutide formulation, a generic version of Victoza® and Saxenda®, widely used for Type-2 diabetes treatment and weight management.
The approval, granted through the Decentralized Procedure (DCP), underscores Biocon and Zentiva’s dedication to offering cost-effective treatment alternatives for patients across the EU.
Biocon shares opened at ₹332.55, reaching a high of ₹336.60 and a low of ₹332.10 today. Over the past 52 weeks, the stock hit a high of ₹395.80 and a low of ₹244.55.
As of 9:28 am, Biocon shares were trading 1.59% higher at Rs 334.80 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
